Does Preimplantation Genetic Testing Increase the Risk of Adverse Clinical Outcomes?

Before 1990, options were limited for couples who were at risk for transmitting a genetic disease or a structural chromosomal abnormality to their children. Couples traditionally underwent invasive procedures such as amniocentesis and chorionic villus sampling, after which termination was offered if the fetus was found to be affected. Many couples chose not to have children at all. Since then, technological advances have allowed preimplantation genetic testing (PGT) to be offered to these couples. Couples who choose PGT undergo in-vitro fertilization (IVF) with intracytoplasmic sperm injection (ICSI), where the oocyte is injected by a single sperm and is then implanted into the mother a few days later. However, in PGT, a few cells are removed and genetically analyzed before implantation to determine whether the embryo has a specific genetic defect or aneuploidy. The purpose of this paper is to determine whether PGT causes adverse clinical outcomes by critically analyzing PGT research studies. Current research does not seem to show any major adverse clinical outcomes after PGT especially in cases of singleton pregnancies. It is important to continue to examine the effects of an embryo biopsy in terms of neonatal and obstetric outcomes, as well as future development